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Summary
Background Exacerbations represent a major source of morbidity and mortality in asthma
and are a prominent feature of poorly controlled, difficult-to-treat disease.
Objective The goal of our study was to provide a detailed characterization of the frequent
exacerbator phenotype and to identify risk factors associated with frequent and seasonal
exacerbations.
Methods Ninety-three severe asthmatics (SA) and 76 mild-to-moderate patients (MA) were
screened and prospectively followed up for 1 year (NCT00555607). Medical history, baseline
clinical data and biomarkers were used to assess risk factors for frequent exacerbations.
Results During the study, 104 exacerbations were recorded in the SA group and 18 in the
MA. Frequent exacerbators were characterized by use of higher doses of inhaled (1700 vs.
800 lg) and oral (6.7 vs. 1.7 mg) glucocorticosteroids, worse asthma control (ACQ score
2.3 vs. 1.4), lower quality of life (SGRQ score 48.5 vs. 33.3), higher sputum eosinophils
(25.7% vs. 8.2%) and a more rapid decline in FEV1/FVC ratio (0.07 vs. 0.01 DFEV1/
FVC, frequent vs. non-frequent, respectively, P < 0.05). Exhaled NO > 45 p.p.b. and a his-
tory of smoking were associated with an increased risk of frequent exacerbations (odds
ratios: 4.32 and 2.90 respectively).
Conclusion and Clinical Relevance We were able to distinguish and characterize a subphe-
notype of asthma subjects – frequent exacerbators – who are significantly more prone to
exacerbations. Patients with FeNO > 45 p.p.b. and a history of smoking are at increased
risk of frequent exacerbations and require careful monitoring in clinical practice.
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Introduction
Acute exacerbations are a major source of morbidity and
mortality in asthma. It has been shown in children that
the costs associated with asthma care are three times
higher in exacerbators as compared to those patients
who did not experience any attacks [1]. Exacerbations
are a prominent feature of poorly controlled and severe
asthma [2]; however, even in patients with mild disease,
the rates of severe exacerbations are high [3]. Recent
ATS/ERS guidelines [4] pointed out that exacerbations
constitute the greatest risk to patients, are the major
cause of stress and anxiety to patients and their families,
and generate the highest costs for the health care system.
Nowadays, a history of exacerbations is incorporated
into the definition of asthma control and the prevention
of asthma exacerbations has been identified as a pri-
*Contributors to the BIOAIR (Longitudinal Assessment of Clini-
cal Course and BIOmarkers in Severe Chronic AIRway Disease)
study are listed in the Appendix.
mary goal in asthma treatment guidelines [5]. Improv-
ing baseline asthma control with inhaled glucocorticos-
teroids can reduce the risk of exacerbations in patients
with atopic asthma. However, a decrease in asthma
symptoms is not always in line with the number or
severity of exacerbations [6]. Thus, it has been hypothe-
sized that baseline disease control and mechanisms
underlying exacerbations are probably driven by differ-
ent factors [2]. In clinical practice, one can easily rec-
ognize a subgroup of asthma patients that experience a
higher rate of exacerbations.
In contrast to chronic obstructive pulmonary disease
[7], the phenotype of frequent exacerbators has not been
clearly characterized in asthma patients. Thus, the pri-
mary goal of our study was to provide detailed character-
istics of frequent exacerbators based on medical history,
physiological variables and biomarkers. Secondary goals
included the identification of risk factors associated with
frequent exacerbations, and a detailed analysis of sea-
sonal (autumn and spring) exacerbations. As two differ-
ent definitions of frequent exacerbations (more than two
events per year [2] or more than three events per year
[8]) are currently in use, we also aimed to study potential
differences in those two approaches.
Methods (for further details, please refer to the
Supporting Information)
Study design
The BIOAIR trial was a partly European Union supported
project on biomarkers and clinical outcomes, with a par-
ticular focus on severe asthma. The study had a two-
group prospective design. Asthma patients were screened
and allocated to severe (SA) or mild-to-moderate asthma
(MA) cohorts. After a 4-week treatment optimization
period, patients were followed up for at least 1 year.
Information regarding lung function, biomarkers
(induced sputum, peripheral blood, exhaled NO), atopy,
medical history, asthma control (evaluated with the use
of the Juniper Asthma Control Questionnaire) [9] and
quality of life (evaluated with the use of St Georges
Respiratory Questionnaire) [10] were collected at base-
line and at consecutive visits. The study was registered
at the clinicaltrials.gov web (NCT00555607) and the pro-
tocol was approved by the ethics review boards and drug
regulatory authorities in the twelve participating centres.
Subjects
Asthma was diagnosed by pulmonary specialists
according to standard criteria [5, 11]. Patients included
in the SA group had been under specialist treatment for
at least 1 year and despite continuous treatment with
high doses of inhaled corticosteroids (ICS; at least
1600 lg/day budesonide or equivalent) had experienced
at least one exacerbation requiring oral steroid treat-
ment in the year preceding inclusion into the study.
Patients in the MA group had stable disease, received
daily treatment with a maximum of 800 lg/day budes-
onide, used short-acting b-agonists (SABA) as needed
but did not require treatment with LABA and had had
neither exacerbations nor hospitalizations in the last
year. All patients gave written informed consent.
Exacerbations
In line with the ATS/ERS recommendations [4], exacer-
bations were defined as events clinically identified to be
outside the patient’s usual range of day-to-day asthma
variation, which are troublesome for patients and require
a change in treatment. Severe exacerbations (including
at least 3 days’ use of oral corticosteroids, an increase
from a maintenance dose of systemic corticosteroids, or
hospitalizations/ED visits) and moderate exacerbations
(defined as a need for change in treatment, but not ful-
filling the criteria of severe exacerbations) were included
in the analysis. Mild asthma exacerbations were not
identified as they could not be distinguished from a
transient loss of asthma control [4]. Frequent exacerba-
tors were defined as those who had two or more exacer-
bations during the 1 year of follow-up, and non-
frequent exacerbators as those who had no exacerba-
tions or up to 1 event. Spring exacerbators were defined
as those who experienced most of exacerbations in April,
May or June, and likewise autumn exacerbators as those
with most exacerbations in October, November and
December. Non-seasonal exacerbators had events- in
other months during the 1 year follow-up period.
Data collection and statistical analysis
Lung function (PEF and FEV1), rescue medication use
(SABA), day and night symptoms and limitation of activ-
ities were recorded daily using electronic diaries (Vitalo-
graph Electronic PEF/FEV1 Diary – XM version,
Vitalograph Ltd., Buckingham, UK). During the study, the
patients were supplied with written cards advising them
to contact the study physician or nurse immediately (all
centres were available 24 h/day and 7 day/week) in case
of a troublesome loss of asthma control (increase in
symptoms and rescue medication use, decrease in daily
activities, or quality of life). Weekly phone calls were
made by study nurse to ensure the patients’ compliance
with the study procedures. Based on medical history,
symptoms, medication use and additional tests, the
responsible physician then labelled the event as an
asthma exacerbation. Data were entered into a central
database through a web-based Case Record Form (eCRF)
system developed specifically for the BIOAIR study.
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Patients’ baseline characteristics are expressed as
mean  standard error of the mean (SEM). Non-para-
metric tests (Mann–Whitney U-test) and chi-square tests
(or Fishers exact test where appropriate) were used.
To identify factors possibly associated with a risk of
frequent or seasonal exacerbations, subjects with
reported exacerbations were compared with applicable
controls (non-frequent or non-seasonal exacerbators). A
multivariate logistic regression model including all
potential predictors with a univariate P-value less than
0.1 was built and adjusted for atopy, sex, age, asthma
severity and smoking status. SPSS version 17.0 software
(SPSS Inc., Chicago, IL, USA) was used for statistical
analysis. P < 0.05 was considered a statistically signifi-
cant difference for all tests. A subanalysis of frequent ex-
acerbators, including patients with three or more
exacerbations was also performed and compared to the whole
group of frequent exacerbators (two or more events).
Results
Patients’ characteristics
One hundred and sixty-nine patients, including 93 SA
and 76 MA, were screened and followed up for at least
1 year. Baseline patient characteristics and demographic
data are displayed in Table 1. Severe asthmatics, in
comparison to MA, were older (50 vs. 42.2 years), had
a higher BMI (28.5 vs. 25.0), lower lung function
(FEV1% of predicted: 70.4 vs. 88.7%) and poorer quality
of life (Juniper ACQ score 2.03 vs. 1.03). Severe asthma
patients were significantly older when their asthma
developed (29.2 vs. 22.2, SA vs. MA).
Exacerbations
The majority of exacerbations were recorded in the SA
group (104 vs. 18 in MA, P < 0.0001). Fifty-two SA
patients (56% of the cohort) experienced 1–6 exacerba-
tions during the 1 year follow-up period. The number
of exacerbations per patient per year was 1.2. Forty-
one patients from the SA group did not have any
exacerbations. Forty-four exacerbations (42.3%) were
regarded as severe based on the predetermined criteria
[4], and in 14 cases (13.7%) hospitalization was neces-
sary. During the 1 year follow-up period, only 16
patients in the MA cohort (22.2%) had in total 18
exacerbations. The number of exacerbations per patient
per year was 0.24. Five exacerbations were severe
(27.8%). No hospitalizations due to asthma exacerba-
tions were reported in the MA group. Thirty one exac-
erbations were recorded in spring time (April, May and
Table 1. Demographic data and baseline characteristics of the BIOAIR study cohort [mean values ( SEM), unless stated differently]. Atopy
defined as at least one positive skin prick test.
Whole study group Severe asthma (SA)
Mild-to-moderate
asthma (MA)
P (SA vs.
MA)
Number of patients (n) 169 93 76 –
Number of exacerbations (n, mean  SEM) 122 (0.72  0.09) 104 (1.2  1.1) 18 (0.24  0.2) < 0.0001
Age (years) (min–max) 46.5  1.04 (18–72) 50.0  1.3 (18 - 72) 42.2  1.5 (20–70) 0.0002
Females (%) 59.2 58 61 0.76*
Age of asthma onset (years) 26.1  1.9 29.2  1.9 22.2  2.2 0.01
FEV1 (% pred) 80.1  1.8 70.4  2.1 88.7  2.1 < 0.0001
FEV1 (L) 2.44  0.07 2.04  0.08 2.79  0.08 < 0.0001
FEV1/FVC 0.69  0.01 0.67  0.01 0.70  0.01 0.035
Reversibility 9.97  0.5 9.4  0.8 10.6  0.7 0.09
ICS [median (mean  SD)] lg beclomethasone
eq.
800 (1416  1015) 1600 (2064  939.7) 800 (614  218.6) < 0.0001
OCS [median (mean  SD; min–max)]
prednisolone eq.
0 mg (2.6  7.6; 0–50) 10 mg (14.1  11.8; 2–50) – –
BMI (kg/m2) 27.0  0.4 28.5  0.6 25.0  0.4 <0.0001
ACQ (Juniper, units) 1.6  0.1 2.03  0.1 1.03  0.7 <0.0001
QoL (SGRQ, units) 36.3  1.8 45.9  2.1 22.5  2.0 <0.0001
CRP (mg/L) 4.9  0.6 6.1  0.9 3.5  0.6 0.01
Atopy (%) 45.0 43.2 48.0 0.64*
FENO (p.p.b.) 43.5  3.9 46.3  6.2 40.1  4.1 0.91
Smoking status (pack years history) 5.0  0.9 4.7  1.1 5.6  1.8 1.0
Sputum cells (9106) 2.5  0.6 3.34  1.02 1.83  0.34 0.38
Sputum eosinophils (%) 11.4  2.1 16.7  3.49 5.79  1.71 0.026
Sputum neutrophils (%) 43.2  2.8 42.2  3.7 44.2  4.4 0.81
Mann–Whitney U-test or *chi-square test (for details, see Supporting Information and references S1, S2, S3).
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June), 46 in autumn (October, November and Decem-
ber) and 45 were outside of these seasons (other
months) (Fig. 1).
Frequent exacerbators
Thirty patients experienced at least two, and 14 patients
had at least three exacerbations during the 1 year fol-
low-up period, and these were therefore classified as
frequent exacerbators. One hundred and thirty-nine
patients had less than two exacerbations and were clas-
sified as non-frequent exacerbators. The majority of fre-
quent exacerbators were from the SA cohort. Frequent
exacerbators used significantly higher doses of inhaled
(1700 vs. 800 lg) and oral (6.7 vs. 1.7 mg) glucocorti-
costeroids, had worse asthma control (ACQ score 2.3 vs.
1.4), a lower quality of life (SGRQ score 48.5 vs. 33.3),
higher CRP level (6.8 vs. 4.3 mg/L) and higher sputum
eosinophils (25.7 vs. 8.2%) at baseline as compared with
non-frequent exacerbators (Table 2). No significant dif-
ferences in baseline characteristics were found between
frequent exacerbators defined by two or more, and
those defined by three or more exacerbations (Table 2).
Change in lung function in frequent exacerbators
The changes in lung function parameters measured over
the 1 year follow-up period (D calculated as value at
visit after 1 year – value at baseline) were compared
between non-frequent and frequent exacerbators (Table
S2). A statistically significant, more rapid decline in
pre-bronchodilator FEV1/FVC ratio was found in fre-
quent exacerbators (DFEV1/FVC = 0.07 vs. 0.01 in
frequent vs. non-frequent, respectively, P = 0.02,
Mann–Whitney U-test). A tendency towards a faster
decline in FEV1% of predicted (DFEV1% pre-
dicted = 8.8 vs. 4.8, in frequent vs. non-frequent
exacerbators) and FVC% of predicted (DFVC% pre-
dicted = 6.6 vs. 2.8) was seen; however, these differ-
ences did not reach statistical significance (P = 0.1 and
P = 0.64 respectively).
Risk factors for frequent exacerbations
The univariate analysis of factors associated with a risk
of frequent exacerbations is presented in Table S4.
When adjusted for possible confounding factors (age,
smoking, atopy, severity of the disease and sex) in a
multivariate logistic regression model (Table 3) exhaled
NO > 45 p.p.b. and a history of smoking were signifi-
cantly associated with an increased risk of frequent
exacerbations, defined as two or more events per year
(odds ratios: 4.32 and 2.90 respectively) (Fig. 2). History
of smoking was significantly associated with an
increased risk of frequent exacerbations defined as
three or more events per year (odds ratio: 3.61) (Table 3
and Fig. 2). Similarly, when the severe asthma cohort
was analysed separately, exhaled NO > 45 p.p.b. and
asthma control (Juniper ACQ > 1.36) were significantly
associated with an increased risk of frequent exacerba-
tions defined as two or more events per year (odds
ratios: 5.98 and 3.65 respectively). There was a ten-
dency towards an increased risk of exacerbations in
past smokers (odds ratio: 2.48, P = 0.06) (Table S5).
Smoking history was the only factor significantly asso-
ciated with an increased risk of frequent exacerbations
defined as three or more events per year (odds ratio:
3.87) (Table S5).
Frequent exacerbators as a distinct phenotype of asthma
We have evaluated the allocation of frequent exacerba-
tors to different phenotypes as based on published, up
to date algorithms [12, 13]. When allocation is defined
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Fig 1. The monthly distribution of exacerbations over 1 year of follow up.
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by physiological variables (lung function, reversibility
and age of onset of the disease) as proposed by Moore
et al. [12], the majority of frequent exacerbators are
found in cluster 4 (low baseline lung function, partially
reversible) (29.9%) and cluster 2 (high baseline lung
function, not reversible, early onset) (29.9%), followed
by cluster 3 (high baseline lung function, not reversible,
late onset) (16.7%), 5 (16.7%) and cluster 1 (high base-
line lung function, reversible) (6.7%). When allocation
is based on biomarkers, namely eosinophils and neu-
trophils in induced sputum [13], the majority of fre-
quent exacerbators can be found in cluster 4 (high
eosinophils and low neutrophils) (44.4%) and cluster 3
(high eosinophils and high neutrophils) (38.9%) fol-
lowed by cluster 1 (low eosinophils and high neutroph-
ils) (11.1%) and cluster 2 (low eosinophils and low
neutrophils) (5.5%) (Fig. S1).
Seasonal exacerbators
Nineteen patients experienced most of their exacerba-
tions in the spring (April, May, June) and 46 in autumn
Table 2. Comparison between frequent exacerbators defined as at least two or at least three events per year of follow-up [mean values ( SEM),
unless stated differently]. Atopy defined as at least one positive skin prick test.
Non-frequent
exacerbators
(< 2 events per year)
Frequent
exacerbators
(≥ 2 events per year)
P (non-
frequent
vs.
frequent
[≥ 2
events per
year]
Frequent
exacerbators
(≥ 3 events per year)
P (non-
frequent
vs.
frequent
[≥ 3
events per
year]
P (frequent
[≥ 2 events]
vs. frequent
[≥ 3 events
per year]
Number of
patients (n)
139 30 – 14 – –
Asthma severity
(SA/MA)
65/74 28/2 < 0.0001* 14/0 < 0.0001* 1.0*
Number of
exacerbations
(n, mean  SEM)
38 (0.3  0.04) 84 (2.8  0.2) < 0.0001 52 (3.7  0.3) < 0.0001 0.003
Age (years)
(min–max)
46.3  1.2 (20–72) 47.4  2.4 (18–70) 0.67 50.9  3.3 (29–69) 0.25 0.39
Females (%) 59 60 1.0* 57 1.0* 1.0*
Age of asthma
onset (years)
26.0  1.6 26.4  3.5 0.91 31.9  5.1 0.29
FEV1 (% pred) 81.25  2.1 75.4  3.4 0.09 79.0  4.9 0.52 0.55
FEV1 (L) 2.47  0.08 2.31  0.15 0.35 2.36  0.21 0.63 0.75
FEV1/FVC 0.69  0.01 0.68  0.02 0.65 0.72  0.02 0.48 0.34
Reversibility 9.9  0.5 8.9  1.5 0.22 8.4  2.0 0.4 0.99
ICS [median
(mean  SD)] lg
beclomethasone eq.
800 (1281  950) 1700 (2024  1063) 0.0001 2200 (2294  1242) 0.002 0.46
OCS [median
(mean  SD;
min–max)]
prednisolone eq.
0 (1.7  5.8; 0–40) 0 (6.7  12.5;0–50) 0.005 0 (8.6  14.7;0–50) 0.003 0.59
BMI (kg/m2) 26.6  0.4 28.4  1.0 0.055 30.1  1.4 0.01 0.37
ACQ (Juniper) 1.4  0.1 2.3  0.2 < 0.0001 2.1  0.2 0.01 0.58
QoL (SGRQ) 33.3  1.9 48.5  3.8 0.0008 52.7  4.0 0.0008 0.49
CRP (mg/L) 4.3  0.6 6.8  1.4 0.046 6.6  1.6 0.07 0.77
Atopy (%) 45.3 40.0 0.67* 50.0 0.78* 0.74*
FENO (p.p.b.) 38.9  3.4 60.6  12.7 0.23 54.4  20.2 0.74 0.73
Smoking status
(pack years history)
4.6  0.9 5.9  2.3 0.77 3.7  0.4 0.93 0.75
Sputum cells (9106) 2.86  0.7 1.3  0.3 0.33 1.7  0.8 0.99 0.56
Sputum eosinophils
(%)
8.2  1.8 25.7  6.9 0.004 21.0  12.5 0.15 0.76
Sputum neutrophils
(%)
43.6  3.1 41.3  7.0 0.76 39.2  13.8 0.79 0.89
Mann–Whitney U-test or *chi-square test (Fisher exact test when appropriate).
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(October, November and December), and these patients
were classified as seasonal exacerbators (spring and
autumn exacerbators respectively) (Fig. 1). A detailed
description of seasonal exacerbators and risk factors for
seasonal exacerbations is presented in the on-line
repository.
Discussion
Exacerbations are important events in the natural his-
tory of poorly controlled asthma. The implications of
these flare-ups include risk of mortality, decreased
quality of life and extensive utilization of health care
resources. In our clinical practice, we can distinguish a
subgroup of asthma patients who are significantly more
prone to exacerbations. In this article, we propose that
these patients should be called ‘frequent exacerbators’,
similar to what has been suggested in COPD patients
[14]. In our article, we provide detailed characteristics
of the frequent exacerbators’ phenotype, based on med-
ical history, physiological variables and biomarkers. We
found that frequent exacerbators use higher doses of
inhaled and oral glucocorticosteroids, have a lower
quality of life and worse asthma control, higher CRP
and sputum eosinophil levels. Exhaled NO above
45 p.p.b. and a history of smoking represent risk factors
for frequent exacerbations. Thus, we have proven that
frequent exacerbators represent a distinct phenotype of
asthma, not yet identified by studies published to date,
neither based on physiological variables [12] nor on
biomarkers [13].
The strength of our study lies in the careful patient
selection, prospective design and long (1 year) follow-
up period. Strict diagnostic criteria were applied to
recruit a group of patients where all possible co-
morbidities and alternative diagnoses were carefully
excluded, and thus, are unlikely to confound the study
results [15]. There are some differences in the basic
characteristics of our frequent exacerbators cohort as
compared to those described in the study by ten Brinke
et al. [8]. In this previous study, it was shown that fre-
quent exacerbators are younger, have a positive family
history of asthma, a higher reversibility rate and higher
bronchial hyper-reactivity as compared to non-frequent
exacerbators. On the other hand, no differences were
found when the intensity of treatment was analysed.
Table 3. Adjusted odds ratios in multivariate logistic regression models for factors associated with risk of frequent exacerbations (defined as two
or more, and three or more exacerbations during 1 year of follow-up).
Factor OR 95% CI P Comments
Frequent exacerbators (two or more exacerbations)
eNO > 45 p.p.b. 4.32 1.02–18.31 0.047 Adjusted for sex, age, smoking, asthma
severity and atopy
Smoking 2.90 1.15–7.35 0.025 Adjusted for sex, age, asthma severity and atopy
Sputum eosinophils ≥ 2% 3.81 0.68–21.43 0.13 Adjusted for sex, age, smoking, asthma
severity and atopy
Juniper ACQ > 1.36 (median) 2.92 0.94–90.30 0.063 As above
FEV1≤70% 1.86 0.70–4.92 0.21 As above
SGRQ>34.6 (median) 1.61 0.52–4.91 0.41 As above
BMI>25 1.16 0.42–3.12 0.77 As above
Frequent exacerbators (three or more exacerbations)
Smoking 3.61 1.09–11.99 0.036 Adjusted for sex, age, asthma severity and atopy
SGRQ > 34.6 (median) 3.46 0.66–18.29 0.14 Adjusted for sex, age, smoking, asthma
severity and atopy
Sputum eosinophils ≥ 2% 3.16 0.204–49.05 0.41 As above
BMI > 25 3.13 0.61–16.17 0.17 As above
Juniper ACQ > 1.36 (median) 1.60 0.38–6.67 0.52 As above
eNO > 45 p.p.b. 1.36 0.205–9.05 0.75 As above
FEV1 ≤ 70% 0.71 0.19–2.54 0.59 As above
0
2
4
6
8
16
18
20
FeNO > 45 p.p.b. Smoking
O
dd
s 
ra
tio
 (O
R
)
0
2
4
10
12
14
Smoking
O
dd
s 
ra
tio
 (O
R
)
(a) (b)
Fig 2. Adjusted odd ratios (and 95% CI) for risk factors of frequent
exacerbations defined as more than two events per year (a) and more
than three events per year (b). Multivariate logistic regression model,
adjusted for age, sex, asthma severity, smoking and atopy.
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One possible explanation may be that despite the appli-
cation of similar inclusion criteria in both studies, dif-
ferent populations of asthma patients were included. In
the ten Brinke study [8], most of the frequent exacerba-
tors represent a group of younger atopic patients with
an early onset of the disease.
We have not found any major differences between
phenotypes of frequent exacerbators defined by two or
more events [2] or three or more events [8]. We hereby
call for a unification of the definitions used in clinical
practice and scientific studies, as this would enable
more direct comparisons of different trials to be made,
as well as improve our understanding of asthma exac-
erbations. As we found that those asthma patients who
experienced two or more exacerbations per year repre-
sent a clear phenotype of frequent exacerbators, we
propose this definition for frequent exacerbators.
A high proportion of frequent exacerbators in the
severe asthmatic group is inherent to the definition of
severe, uncontrolled asthma, and in fact, a history of
previous exacerbations was an inclusion criterion in
our study [11] that has also been used by others [16].
To avoid possible bias, we used asthma severity as a
confounding factor in the multivariate analysis. More-
over, we have evaluated risk factors separately for the
severe asthma cohort, and these showed no differences
compared to the whole study population.
Recent exacerbations represent an important indepen-
dent predictor of future exacerbations in patients with
severe or difficult-to-treat asthma [17]. We have found
that despite intensive anti-inflammatory treatment,
these patients are still at risk of high numbers of exacer-
bations, and this is on par with the North-American
severe asthma cohort data [18]. Similarly, in the GOAL
study, it has been shown that exacerbations could be
reduced in the majority of patients by increasing the
daily dose of inhaled corticosteroids and LABA. How-
ever, in a proportion of patients, it was not possible to
achieve good control of the disease on doses of inhaled
corticosteroids reaching 1000 lg of fluticasone and
even oral steroids [19]. In our study, frequent exacerba-
tors were characterized by high levels of sputum eosin-
ophils (> 25%) despite intensive treatment (> 2000 lg
of beclomethasone). This suggests that the recommended
treatment may not be efficacious in reducing the level
of eosinophilic inflammation in the airways and the rate
of exacerbations in this phenotype. Recent trials showed
that use of the anti-interleukin (IL)-5 monoclonal anti-
body (mepolizumab) [20–22] or anti-tumour necrosis
factor a [22] may represent a promising strategy.
Another option includes the administration of high
doses of systemic corticosteroids, as it has been proven
that persistent sputum eosinophilia is not a refractory
phenomenon despite extensive anti-asthma treatment
but is still sensitive to high-dose systemic corticosteroids
[23]. However, data in this field are conflicting and
proof of the opposite has been reported, reviewed in
[24]. Those severe asthmatics who suffer from frequent
exacerbations differ from non-frequent exacerbators in
terms of quality of life and sputum eosinophilia (Table
S2). Thus, it may be hypothesized that this increase in
exacerbation rate merely represents a continuum of
severity related to eosinophilic inflammation and clini-
cal control. The design of the current trial does not
enable us to gain insight into the mechanisms underly-
ing the observed differences and thus we do not discuss
endotypes, instead we propose a new clinically defined
phenotype. The most probable reasons for frequent
exacerbations may include a lack of disease control
with regards to eosinophilic inflammation (possibly
due to a lack of compliance to medications, the use of
inadequate doses of medications, glucocorticosteroid
resistance, comorbidities, or other as yet unknown
mechanisms. Nevertheless, we believe that it is impor-
tant to identify this subpopulation of asthma patients in
clinical practice. Such an approach enables us to evalu-
ate the most probable reasons for frequent exacerba-
tions, as well as identify this population for further
mechanistic studies.
It could be argued that the reason for the high rate
of exacerbations in our study is poor adherence to pre-
scribed treatment. Several groups have shown that
compliance with doctors’ recommendations is one of
the major problems in difficult-to-treat asthmatics.
Genuine steroid unresponsiveness is rare [25] and in
most cases (30–60%) [26, 27], poor control results from
non-adherence, comorbidities, poor inhalation tech-
niques or wrong diagnosis. However, in this study, good
adherence to the recommended treatment was achieved
by the involvement of highly devoted clinical centres,
the treatment optimization period at inclusion, repeated
instruction in inhalation technique, personalized treat-
ment plans and the careful follow-up of all included
patients. Nevertheless, adherence has not been evalu-
ated using unbiased methods (such as the memory chips
of meter dose inhalers), which is a clear limitation of
our report. On the basis of the results of our study, we
propose that high levels of exhaled NO or eosinophils
in induced sputum along with low asthma control
(evaluated using the Juniper ACQ) could be regarded as
warning signals in our every day clinical practice. In
such cases, adherence to the controller medication
should be checked before any other therapeutical
options are introduced.
Allocation of our patients to clusters based on previ-
ously published proposals [12, 13] revealed that most of
the frequent exacerbators belong to a cluster with low
baseline lung function which is partially reversible, or a
cluster with a high baseline lung function that is not
reversible, with early onset of the disease [12]. Taking
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biomarkers into consideration most of our frequent
exacerbators belong to a cluster characterized by high
sputum eosinophils with either high or low neutrophils
[13]. When analysing baseline clinical characteristics,
physiological variables and biomarkers, we found that
those patients characterized by exhaled NO levels
> 45 p.p.b. and had a history of smoking represented a
group of asthmatics at higher risk of frequent exacerba-
tions. Again, this is in accordance with the North-
American severe asthma network data [28]. What is
particularly striking in our study is the tendency
towards a steeper decline in lung function among the
frequent exacerbators. The impact of exacerbations on
decline in lung function has been reported in asthma
[29] and COPD patients [14]. However, this finding
requires confirmation in studies with follow-up periods
longer than 1 year.
We did not find any significant differences in basic
characteristics between seasonal (spring or autumn) and
non-seasonal exacerbators; thus, the phenotype of
seasonal exacerbator could not be distinguished in our
study. Sputum eosinophils ≥ 2% and male sex were asso-
ciated with a significantly higher risk of developing
spring exacerbations, which is not surprising as those
exacerbations are most probably associated with atopic
status, allergen sensitization and allergen exposure [30],
in contrast to autumn exacerbations, which are most
likely associated with viral infections [31]. The BIOAIR
study was a multi-centre, trans-European trial with
patients included from Scandinavia to the Mediterranean
region, with different allergies and different seasons of
exposure. As patients experienced exacerbations in dif-
ferent months, it was difficult to clearly allocate seasonal
or non-seasonal exacerbators, which is a limitation of
our study. Moreover, viral infections may occur through-
out the year (rhinovirus in the autumn, influenza in the
late winter to early spring), making any seasonal predi-
lection difficult to interpret.
The ability to identify patients with the greatest risk
of future exacerbations is vital for developing effective
preventive strategies, reducing health care costs and
achieving good asthma control. In our article, we pres-
ent the clinical characteristics of the frequent exacerba-
tors’ phenotype as well as the risk factors for frequent
flare-ups of the disease. Methods such as exhaled NO
measurement, are widely used, thus implementation of
our findings into treatment guidelines would enable
easier identification of patients who are at risk, increase
monitoring and improve every day clinical care. Appro-
priate long-term management strategies coupled with
improved compliance should reduce mortality and mor-
bidity associated with asthma exacerbations [31, 32],
however, further studies are needed to clarify the opti-
mal treatment options for frequent exacerbators. The
fact that this group of severe asthma patients, who are
under specialist care in highly specialized centres still
remain symptomatic and face frequent exacerbations,
emphasizes the need for more research into pathoge-
netic mechanisms and novel therapeutic approaches.
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